Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 3/20 | 0.32 |
| ▸ | NOS1 | P29475 | 3/20 | 0.32 |
| ▸ | NOS2 | P35228 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19692314 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL1611049 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL1476715 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL1476747 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL2961154 | 0.94 | ALOX5 (0.50) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL2966938 | 0.94 | ALOX5 (0.50) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL18657390 | 0.88 | ALOX5 (0.65) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL29971764 | 0.88 | ALOX5 (0.65) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL18685663 | 0.88 | ALOX5 (0.65) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL9376923 | 0.87 | ALOX5 (0.43) | ALOX5ALDH1A1EPHX1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024014512-A1 | LYOPHILIZED COMPOSITION OF NUCLEIC-ACID-LOADED LIPID NANOPARTICLES | 日油株式会社 | 2024-01-18 | — | — | WO | disclosed |
| WO-2024014511-A1 | LIPID NANOPARTICLE AND METHOD FOR PRODUCING SAME, NUCLEIC ACID-ENCAPSULATED LIPID NANOPARTICLE AND METHOD FOR PRODUCING SAME, AND METHOD FOR INDUCING ACQUIRED IMMUNITY IN LIVING BODY BY USING NUCLEIC ACID-ENCAPSULATED LIPID NANOPARTICLE | 日油株式会社 | 2024-01-18 | — | — | WO | disclosed |
| WO-2023190176-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | 日油株式会社 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023190175-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO PERIPHERAL BLOOD MONONUCLEAR CELLS, AND METHOD FOR DELIVERING NUCLEIC ACID TO PERIPHERAL BLOOD MONONUCLEAR CELLS USING SAME | 日油株式会社 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023190170-A1 | METHOD FOR PRODUCING NUCLEIC ACID-ENCAPSULATED LIPID NANOPARTICLES, METHOD FOR PRODUCING PHARMACEUTICAL COMPOSITION CONTAINING SAID LIPID NANOPARTICLES, AND METHOD FOR INTRODUCING NUCLEIC ACID INTO CELL OR TARGET CELL | 日油株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-20190336611-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CUREVAC AG (DE) | 2019-11-07 | — | — | US | disclosed |
| EP-3468608-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CureVac AG (DE) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017212006-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CUREVAC AG (DE) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336611-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | PHAX, LNPEP, PITPNB | ALOX5 3408/4885ALDH1A1 4507/4885EPHX1 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.